content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Brainstorm Cell Therapeutics Inc. (BCLI)

3.93
-0.05
(-1.26%)
Sep 11, 4:00PM EDT
content_middle

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.

BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.

Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.

Previous Close: 
4.25
Open: 
4.31
Bid: 
4.20
Ask: 
4.49
1yr Target Price: 
9.00
Day's Range: 
4.20 - 4.33
52wk Range: 
2.88 - 5.35
Volume: 
51022
Average Daily Volume: 
110611
Market Capitalization: 
81.23M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
20.67M
content_right

Pages